<DOC>
	<DOCNO>NCT00675597</DOCNO>
	<brief_summary>The purpose study determine whether combination drug docetaxel ( Taxotere ® ) , plus vinorelbine ( Navelbine ® ) , result few side effect cisplatin chemotherapy , thereby improve delivery chemotherapy patient . Another purpose study determine whether third drug , bevacizumab ( Avastin® ) , may deliver safely docetaxel plus vinorelbine patient eligible receive bevacizumab .</brief_summary>
	<brief_title>Docetaxel ( Taxotere ) , Vinorelbine , Bevacizumab , Adjuvant Chemotherapy Patients With Resected Stage I-III Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Patients must least 2 week status post complete ( R0 ) surgical resection pathologicallyproven NSCLC ( stage IAIIIB ) . Pathology review perform independently MSKCC . Patients eligible unfit cisplatinbased adjuvant chemotherapy base specify clinical criterion ( list ) . Allergy cisplatin Baseline hearing loss ( define subjective baseline hearing deficit , even require hear aid intervention , interfere activity daily life ( CTCAE grade &gt; equal 2 ) Baseline renal insufficiency ( defined creatinine clearance &lt; equal 60 ml/min calculate equation Cockcroft Gault use patient 's age , weight ( kg ) , serum creatinine ( mg/dl ) . Performance status 70 % Karnofsky scale . Congestive heart failure New York Heart Association functional classification &gt; equal II , characterize fatigue , dyspnea symptom limit activity daily life . Patient refuse take cisplatin . Age &gt; equal 18 Performance Status Karnofsky &gt; equal 70 % Peripheral neuropathy must &lt; grade 1 Hematologic ( minimal value ) Absolute neutrophil count &gt; equal 1,500/mm3 Hemoglobin &gt; equal 8.0 g/dl Platelet count &gt; equal 100,000/mm3 Hepatic Total Bilirubin &lt; equal 1.5 x ULN AST ALT Alkaline Phosphatase must within range allow eligibility Women childbearing potential must negative pregnancy test . Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter . Patients consider treatment bevacizumab must urine protein : creatinine ( UPC ) ratio &lt; 1.0 screen MRI brain CT brain IV contrast show evidence brain metastasis within 3 month study entry &gt; 16 week postop Prior postoperative radiation &gt; 1 cycle prior adjuvant chemotherapy Patients history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 . Women pregnant , breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Bevacizumab ( Avastin )</keyword>
	<keyword>Taxotere ( Docetaxel )</keyword>
	<keyword>Vinorelbine Tartrate ( Navelbine )</keyword>
	<keyword>07-178</keyword>
</DOC>